eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase II trial of bevacizumab (IND# 7921, Avastin) and temsirolimus (IND# 61010, Torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Intervention
  6. Intervention
    Vinorelbine ditartrate - cyclophosphamide
  7. Additional Topic(s)
    Antineoplastic combined chemotherapy
  8. Resource Description
    Vinorelbine ditartrate and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread or carry tumor-killing substances to them. Bevacizumab may also stop the growth of rhabdomyosarcoma by blocking blood flow to the tumor. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given together with bevacizumab or temsirolimus in treating rhabdomyosarcoma.
  9. Contact
    Berenberg, Jeffrey
  10. PI
    Wilkinson, Robert, M.D.
  11. Topic
  12. Study Population
    Males and females up to 29 years with a previous histological verification of rhabdomyosarcoma at original diagnosis.
  13. Website(s)
  14. Funded by
    Children's Oncology Group
  15. Phase
    Phase 2 clinical trial
  16. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016